Nuclear pore complex interacting protein family member A6 (NPIPA6)

Nuclear pore complex interacting protein family member A6 (NPIPA6) is a putative member of the nuclear pore complex interacting protein family. However, NPIPA6 is a predicted gene product with no well-characterized protein function, molecular pathway, or established biological or disease role. It is recognized as a gene listed in human genome databases such as Ensembl (ENSG00000183889), UniProt (P0DXC3), and HGNC. There is no substantial literature indicating that NPIPA6 is a functionally characterized nucleoporin, involved in canonical nuclear pore complex assembly, or serves a defined biological role or therapeutic target. As such, NPIPA6 should not be confused with well-established nuclear pore complex proteins (nucleoporins) like NUP93, NUP98, NUP205, or NUP62, which have recognized structural and functional roles in the nuclear envelope and nucleocytoplasmic transport[2][1][3][5][7]. Key clarifications based on current knowledge and sources: - NPIPA6 is not recognized as a canonical nucleoporin, receptor, enzyme, transporter, or established therapeutic target[2]. - It appears primarily in gene and protein sequence databases without experimental validation of a cellular function or disease association. - There are no established drugs, disease roles, safety concerns, or biomarker uses related to NPIPA6. - The term "nuclear pore complex-interacting protein family" here refers to a genomic family with little or no annotated experimental characterization and should not be equated with validated NPC components[2]. Summary judgment: NPIPA6 is a predicted gene with limited or no characterized function, is not a validated therapeutic or biological target, and there is insufficient data for classification in most requested categories. It is likely inappropriate or incorrect to list it as a target in translational or drug discovery contexts[2].

Other names

NPIPA6NPIPA5Lnuclear pore complex-interacting protein family member A6